STOCK TITAN

OptiNose, Inc. - OPTN STOCK NEWS

Welcome to our dedicated page for OptiNose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on OptiNose stock.

OptiNose, Inc. (NASDAQ: OPTN), founded in 2010 and headquartered in Yardley, Pennsylvania, is a global specialty pharmaceutical company focused on improving the lives of patients treated by ear, nose, and throat (ENT) and allergy specialists. The company is known for its innovative approach to pharmaceutical development and commercialization, aiming to offer value to both the healthcare system and its stakeholders.

OptiNose's flagship product is XHANCE (fluticasone propionate) nasal spray, a unique therapeutic that utilizes the proprietary Exhalation Delivery System (EDS). This system delivers a topical corticosteroid deep into the nasal passages to treat chronic rhinosinusitis with nasal polyps. Unlike traditional nasal sprays, XHANCE targets inflammation high and deep within the nasal passages, reaching areas previously inaccessible by standard treatments.

Recently, XHANCE was approved by the FDA for the treatment of chronic rhinosinusitis without nasal polyps, expanding its potential patient base significantly. This approval was backed by robust clinical data from the ReOpen program, consisting of two global, randomized, double-blind, placebo-controlled Phase 3 trials. These trials demonstrated significant improvement in both symptoms and inflammation for patients with chronic sinusitis, with or without nasal polyps. Some common adverse reactions included epistaxis, headache, and nasopharyngitis, consistent with its labeled safety profile.

OptiNose continues to innovate, working on faster and cost-effective product developments and exploring new commercial models. The company collaborates with ENT and allergy specialists to bring breakthrough treatments to patients, focusing on efficiency and effectiveness in all its operations. OptiNose's commitment to values and ethical practices ensures their dedication to patient care and improved health outcomes.

For the latest updates and detailed information on OptiNose's financial performance, current projects, and strategic developments, visit their website or follow them on social media platforms like X and LinkedIn.

Rhea-AI Summary

Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in treatments for ENT and allergy patients, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ.

The presentation, scheduled for May 20, 2024, at 11:30 a.m. ET, will feature a company overview and business update from Optinose's management team.

The live presentation will be webcast, and a replay will be available for 30 days on the Optinose website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
conferences
-
Rhea-AI Summary

Optinose (NASDAQ:OPTN) reported Q1 2024 net revenue of $14.9 million for XHANCE, marking a 26% increase from Q1 2023. The company forecasts full-year 2024 XHANCE net revenues between $85-$95 million, with peak revenue expectations of at least $300 million. Optinose anticipates positive GAAP income for 2025. In March 2024, the FDA approved XHANCE for chronic rhinosinusitis without nasal polyps, significantly expanding its market. The approval of a second manufacturing site and a $55 million direct offering were also highlighted. Despite these advancements, Q1 2024 saw a net loss of $14.1 million, and operating expenses are projected between $95-$101 million for 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
-
Rhea-AI Summary

Optinose, a pharmaceutical company specializing in ENT and allergy treatments, will announce its first quarter 2024 financial results on May 14, 2024. The company will host a conference call to discuss the results and corporate updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
Rhea-AI Summary

Optinose, a pharmaceutical company specializing in ENT and allergy treatments, announced a $55 million registered direct offering. The offering, led by Nantahala Capital and The D. E. Shaw Group, aims to fund operations through 2025. With a post-offering cash balance of approximately $100 million, the company expects XHANCE net revenues to range between $85 to $95 million for the full year 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
-
Rhea-AI Summary
Optinose announces corporate updates and preliminary first quarter 2024 XHANCE net revenue of $14.9 million. The recent FDA approval for a new indication for chronic rhinosinusitis without nasal polyps in patients 18 years and older is a significant milestone. The Company expects peak XHANCE net revenues to exceed $300 million with incremental spend due to leveraging its current commercial infrastructure. They plan to reach an estimated 3 million patients with chronic sinusitis cared for by ENT and Allergy specialists and potentially expand the market opportunity to over 30 million patients by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
-
Rhea-AI Summary
Optinose (NASDAQ:OPTN) will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024. The presentation will be available via webcast on the Optinose website with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
conferences
Rhea-AI Summary
Optinose (OPTN) receives FDA approval for XHANCE nasal spray to treat chronic rhinosinusitis without nasal polyps, marking a significant breakthrough in treating a debilitating condition affecting millions of adults in the U.S. The drug-device combination product demonstrated a statistically significant reduction in symptoms, sinus inflammation, and acute exacerbations in clinical trials. XHANCE uses a proprietary Exhalation Delivery System to target areas of inflammation deep in the nose. The approval is a crucial advancement in providing effective treatment options for patients suffering from chronic sinusitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary
Optinose (OPTN) reports fourth quarter and full year 2023 financial results, with XHANCE net revenue of $19.9 million and $71.0 million. The company is awaiting FDA approval for XHANCE for chronic sinusitis treatment by March 16, 2024. Despite revenue decreases, operational efficiency improved, with a net loss of $10.0 million for Q4 2023 and $35.5 million for full year 2023. Cash and cash equivalents stand at $73.7 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Summary
Optinose (OPTN) will host a conference call on March 7, 2024, to discuss financial results for the fourth quarter of 2023 and corporate updates. Participants can join via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
Rhea-AI Summary
Optinose (NASDAQ:OPTN) announced the peer-reviewed publication of results from two Phase 3 Clinical Trials evaluating XHANCE for the treatment of chronic sinusitis. The trials showed a significant reduction in symptoms and sinus opacification in patients with chronic rhinosinusitis. XHANCE is a drug-device combination product that uniquely combines a widely used nasal anti-inflammatory drug with an innovative delivery system designed to deliver the medication high and deep into difficult-to-access sinuses and sinonasal drainage tracts. The FDA Supplemental New Drug Application has been filed with a target goal date of March 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags

FAQ

What is the current stock price of OptiNose (OPTN)?

The current stock price of OptiNose (OPTN) is $6.5 as of January 3, 2025.

What is the market cap of OptiNose (OPTN)?

The market cap of OptiNose (OPTN) is approximately 65.6M.

What is OptiNose, Inc.?

OptiNose, Inc. is a global specialty pharmaceutical company focused on developing and commercializing innovative treatments for patients treated by ear, nose, and throat (ENT) and allergy specialists.

What is XHANCE?

XHANCE is a nasal spray developed by OptiNose that uses the Exhalation Delivery System (EDS) to deliver a corticosteroid deep into the nasal passages, primarily for treating chronic rhinosinusitis with and without nasal polyps.

What recent approval did OptiNose receive from the FDA?

The FDA recently approved XHANCE for the treatment of chronic rhinosinusitis without nasal polyps, expanding its therapeutic use.

What is the ReOpen program?

The ReOpen program consisted of two Phase 3 clinical trials that evaluated the efficacy and safety of XHANCE for treating chronic rhinosinusitis, both with and without nasal polyps.

What common side effects are associated with XHANCE?

Common side effects of XHANCE include epistaxis (nosebleeds), headache, and nasopharyngitis.

How does OptiNose's Exhalation Delivery System (EDS) work?

The EDS technology in XHANCE allows for the delivery of medication high and deep in the nasal passages, targeting areas of inflammation that are difficult to reach with standard nasal sprays.

What is chronic rhinosinusitis?

Chronic rhinosinusitis is a long-term inflammation of the sinuses that can cause symptoms like nasal congestion, facial pain, and nasal discharge. It often requires medical treatment for symptom relief.

Where is OptiNose headquartered?

OptiNose is headquartered in Yardley, Pennsylvania.

How does OptiNose create value for the healthcare system?

OptiNose focuses on faster, less costly product development and innovative commercial models, aiming to improve patient outcomes while creating value for the healthcare system and stakeholders.

Where can I learn more about OptiNose and its products?

You can learn more about OptiNose and its products by visiting their website or following them on social media platforms like X and LinkedIn.
OptiNose, Inc.

Nasdaq:OPTN

OPTN Rankings

OPTN Stock Data

65.56M
9.44M
6.21%
78.44%
4.88%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
YARDLEY